149 related articles for article (PubMed ID: 37424349)
1. Nanotechnological Advancements for the Theranostic Intervention in Anaplastic Thyroid Cancer: Current Perspectives and Future Direction.
Uppalapati SS; Guha L; Kumar H; Mandoli A
Curr Cancer Drug Targets; 2024; 24(3):245-270. PubMed ID: 37424349
[TBL] [Abstract][Full Text] [Related]
2. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.
Milosevic Z; Pesic M; Stankovic T; Dinic J; Milovanovic Z; Stojsic J; Dzodic R; Tanic N; Bankovic J
Transl Res; 2014 Nov; 164(5):411-23. PubMed ID: 25016932
[TBL] [Abstract][Full Text] [Related]
3. Low intensity focused ultrasound (LIFU) triggered drug release from cetuximab-conjugated phase-changeable nanoparticles for precision theranostics against anaplastic thyroid carcinoma.
Wang Y; Sui G; Teng D; Wang Q; Qu J; Zhu L; Ran H; Wang Z; Jin C; Wang H
Biomater Sci; 2018 Dec; 7(1):196-210. PubMed ID: 30422139
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
[TBL] [Abstract][Full Text] [Related]
5. Precision Medicine Approach to Anaplastic Thyroid Cancer: Advances in Targeted Drug Therapy Based on Specific Signaling Pathways.
Samimi H; Fallah P; Naderi Sohi A; Tavakoli R; Naderi M; Soleimani M; Larijani B; Haghpanah V
Acta Med Iran; 2017 Mar; 55(3):200-208. PubMed ID: 28282720
[TBL] [Abstract][Full Text] [Related]
6. PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer.
Wong K; Di Cristofano F; Ranieri M; De Martino D; Di Cristofano A
Endocr Relat Cancer; 2019 Apr; 26(4):425-436. PubMed ID: 30699064
[TBL] [Abstract][Full Text] [Related]
7. Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma.
von Roemeling CA; Copland JA
Expert Opin Ther Targets; 2016; 20(2):159-66. PubMed ID: 26414044
[TBL] [Abstract][Full Text] [Related]
8. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
Xing M
Thyroid; 2010 Jul; 20(7):697-706. PubMed ID: 20578891
[TBL] [Abstract][Full Text] [Related]
9. [Anaplastic thyroid carcinoma : new therapeutic approaches].
Stamatiou A; Herrera-Gómez RG; Szturz P; Bisig B; Romano E; Sykiotis G; Gorostidi F; La Rosa S; Kopp P; Cristina V
Rev Med Suisse; 2021 May; 17(739):962-966. PubMed ID: 34009754
[TBL] [Abstract][Full Text] [Related]
10. Antitumor Activity of Berberine by Activating Autophagy and Apoptosis in CAL-62 and BHT-101 Anaplastic Thyroid Carcinoma Cell Lines.
Shi XZ; Zhao S; Wang Y; Wang MY; Su SW; Wu YZ; Xiong C
Drug Des Devel Ther; 2023; 17():1889-1906. PubMed ID: 37397788
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel therapeutic targets in anaplastic thyroid carcinoma using functional genomic mRNA-profiling: Paving the way for new avenues?
Jonker PK; van Dam GM; Oosting SF; Kruijff S; Fehrmann RS
Surgery; 2017 Jan; 161(1):202-211. PubMed ID: 27865593
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances of Nanotechnology in the Diagnosis and Therapy of Triple- Negative Breast Cancer (TNBC).
Kanugo A; Gautam RK; Kamal MA
Curr Pharm Biotechnol; 2022; 23(13):1581-1595. PubMed ID: 34967294
[TBL] [Abstract][Full Text] [Related]
13. A case of osteoclastic variant of anaplastic thyroid carcinoma: Diagnostic and prognostic marker studies by cytology.
Bantumilli S; Zhu LC; Sakthivel M; Dodd L
Diagn Cytopathol; 2022 Dec; 50(12):E357-E360. PubMed ID: 35929756
[TBL] [Abstract][Full Text] [Related]
14. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
[TBL] [Abstract][Full Text] [Related]
15. PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration.
Che HY; Guo HY; Si XW; You QY; Lou WY
Tumour Biol; 2014 Sep; 35(9):8659-64. PubMed ID: 24867098
[TBL] [Abstract][Full Text] [Related]
16. TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma.
Seok JY; Astvatsaturyan K; Peralta-Venturina M; Lai J; Fan X
Int J Surg Pathol; 2021 Jun; 29(4):368-377. PubMed ID: 33289434
[TBL] [Abstract][Full Text] [Related]
17. The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy.
Kasaian K; Wiseman SM; Walker BA; Schein JE; Zhao Y; Hirst M; Moore RA; Mungall AJ; Marra MA; Jones SJ
BMC Cancer; 2015 Dec; 15():984. PubMed ID: 26680454
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.
Murugan AK; Xing M
Cancer Res; 2011 Jul; 71(13):4403-11. PubMed ID: 21596819
[TBL] [Abstract][Full Text] [Related]
19. Deregulation of EGFR/PI3K and activation of PTEN by photodynamic therapy combined with carboplatin in human anaplastic thyroid cancer cells and xenograft tumors in nude mice.
Biswas R; Mondal A; Ahn JC
J Photochem Photobiol B; 2015 Jul; 148():118-127. PubMed ID: 25910816
[TBL] [Abstract][Full Text] [Related]
20. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
